FDA – Page 56 – Policy & Medicine

FDA: Food and Drug Administration Safety and Innovation Act (FDASIA) and Patient Focused Drug Development

FDA Outlines Warning Letters for Promotion of Prescription Pharmaceuticals

FDA Releases Final Risk Evaluation and Mitigation Strategies (REMS) for Extended Release/Long Acting Opioids Including a Prescriber Education Program

FDA User Fee Acts: Congress Drops Limits on Conflict of Interest Wavers

FDA: Risk Evaluation and Mitigation Strategies (REMS) Paper on Program Evaluations and Outcomes

FDA Reports Fewer Number of New Drug Shortages

Former FDA Commissioner Calls for End of FDA Conflict of Interest Rules

FDA: Guidance Drug Safety Information and Communications to the Public

FDA: PFUFA – Senate Introduces Bi-Partisan Legislation on Drug Shortages and Fast Track Product Approvals, and Other Issues

FDA: Committee Recommends Exploring Anti-NGF Biologics for Chronic Pain Management